

# NATIONAL TUBERCULOSIS, LEPROSY & LUNG DISEASE PROGRAM CATEGORY IV DR TB - 03 FACILITY REGISTER



### **Revised case Definitions**

A bacteriologically confirmed TB case-has a positive specimen by smear microscopy, culture or Xpert MTB/RIF).

A **clinically diagnosed** TB Case is one who does not fulfill the criteria for bacteriological confirmation but has been diagnosed with active TB by a Clinician who has decided to give the patient a full course of TB treatment. Clinically diagnosed cases found to be bacteriologically positive (before or after starting treatment) should be reclassified as bacteriologically confirmed.

### **Definitions**

- 1. **Monoresistance (MR):** resistance to one first-line anti-TB drug only.
- 2. **Rifampicin resistance (RR TB):** resistance to Rifampicin detected using phenotypic or genotypic methods.
- 3. **Polydrug resistance (PDR TB):** resistance to more than one first-line anti-TB drug (other than both Isoniazid and Rifampicin).
- 4. **Multidrug resistance (MDR TB):** resistance to both Isoniazid and Rifampicin with or without resistance to other first-line drugs.
- 5. **Pre-XDRTB: MDRTB** with resistance to either Fluoroquinolone or a second-line injectable drugs (Capreomycin, Kanamycin and Amikacin)
- 6. **Extensively drug resistance (XDR TB): MDR TB** with resistance to both Fluoroquinolone and to at least one of three second-line injectable drugs (Capreomycin, Kanamycin and Amikacin.

	Classification of Category IV TB Patients
New (N)	Patients who have never received anti-tuberculosis treatment, or who have received anti-tuberculosis treatment for less than one month. (Note: patients who had DST at the start or within one month of a WHO regimen and are then switched to a second line regimen because of resistance are placed in this group, even if they received more than one month of Category I treatment).
Relapse (R)	Patients previously treated for tuberculosis that has been declared cured or treatment completed, and then diagnosed with MDR-TB.
Return after loss to follow up	Patients who return to treatment with confirmed MDR-TB after interruption of treatment for two months or more
After failure of First Line Treatment (FFT)	Patients who return after having failed the first treatment i.e smear positive at earliest, month 5
After failure of Retreatment (FRT).	Patients who return after having failed the re-treatment regimen.
Transfer in (TI)	Patients who have been transferred from another register for treatment of drug- resistant TB to second line treatment. Their outcomes should be reported to the transferring unit so that it can report their outcomes in the cohort in which they originally started MDR-TB treatment.

Outcomes	Definition
Treatment Completed (TC)	DRTB patient who has completed Treatment as recommended Without evidence of failure BUT no record that three or more Consecutive cultures taken at least 30 days apart are negative after the intensive phase.
Cured (C)	DRTB patient who completes treatment with three or more consecutive negative cultures taken at least 30 days apart after the intensive phase.
Death (D)	A patient who dies from any cause while on DR-TB treatment.
Loss to Follow Ups (LTFU)	A patient who interrupts DR-TB treatment for two or more consecutive Months.
Treatment failure (F)	Treatment terminated or need for permanent regimen change of at Least two anti-TB drugs because of:  • Lack of conversion by the end of the intensive phase; or  • Bacteriological reversion in the continuation phase after conversion to negative  • Evidence of additional acquired resistance to fluoroquinolones or Second-line injectable drugs; or  • Adverse drug reactions
Not evaluated (NE)	A patient for whom no treatment outcome assigned. (This includes cases "transferred out" to another treatment unit and whose treatment outcome is unknown).

## **CATEGORY IV REGISTER**

	ıtion No.	tion			VEMIS No.	<u>.</u>	m/yyyy)					Place of				DR-TB	on for ng into register ppropri- ely)	Ge	ne Xp	ert			cat fille car	egory ed in v	/ IV p when full h	atien the i	it. If the results y of DS	e DST is s are kn	esting ( being s pendi lown. So ) R=Res	ng it s ee trea	hould atmen	be t			r DRTB before? Yes/No	DR-1 treatm		Star trea me mon	at- nt	Monti	n 1	Month :	2 M	onth 3
Serial No.	Sub County Registration No.	Date of Registration	Name in full (Three names)	Sex (M/F)	National ID Number/NEMIS No.	NHIF Number	Date of Birth (dd/mm/yyyy)	Age - Year(s)/Month(s)	Weight at Registration	Height at Registration	BMI/Z score/BMI for age	residence Mobile No (Patient & Treatment supporter)	Occupation (specify)	Type of TB (P/EP)	EPTB Specify site	Bacteriologically confirmed	Clinically Diagnosed	Date sample collected	Date results received	Gene Expert results	Registration group	Resistance Pattern	R	н	Z	E	Km	Am	Cm	Fq	Pto/Eto	Others specify	Date sample taken for DST	Date DST results received	Has the patient ever been treated for	Initial Regimen and Start Date	Modified Regimen (in drug initials) Date started	Smear	Culture	Smear	Culture	Smear	Culture	Smear Culture
																																			-									
																																			_									
																																			-									
																																			-									

	Registration Group
N	New
R	Relapse
LTFU	Loss to follow-up
FFT	After failure of treatment with first line drugs
FRT	After failure of treatment with first line drugs
TI	Treatment in
0	Other

	Resistance Patterns
MDR	Multi drug resistant TB
PRE XDR	Pre-Extensively drug resistance TB
XDR	Extensively drug resistance TB
PDR	Poly drug resistant TB
MR	Mono drug resistant TB (Except RR)
RR	Rifampicin Mono resistant

		GeneXpert Results
	TS	MTB detected, rifampicin resistance not detected
-	RR	MTB detected, rifampicin resistance detected
-	TI	MTB detected, rifampicin resistance indeterminate
	N	MTB not detected
1	I	Invalid/No results/Error

Nutrition support								
NC	Nutrition counselling							
RUTF	Therapeutic feed							
FBF	Supplementary feed							
Vitamin A								
Pyridoxine								
ND	Not done							

Z score/BMI for age/BMI								
Severely malnourished	<16 / < -3SD							
Moderately malnourished	16 - 18.5 / < -2SD							
Normal	18.5 -24.9 / > - 1SD							
Overweight	25 - 30 / > - 2SD							
Obese	>30 /> -3SD							

# Smear (S) and Culture (c) results during treatment

Mo	nth	Mon	nth	Mont	h	Mont	h N	lon 8	th	Mon	- 1	Moi		1	onth	 ontl	h	Mor	- 1	Mo 1		ı	nth	onth	- 1	lon	- 1	Mor 18		Mo 1		1	nth	1	onth 21	onth	- 1	onth	 onth				HIV I	nforma	ation					
Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture		Culture	Smear	Culture				Cutture		Culture	Smear		Smear						Smear	Culture	Smear	Culture	Smear								Is the Patient Diabetic? Y/N	Other Comobidities	V Doc /Nog /Not Doc /Nocling	TIV Pos/ Neg/ Not Done / Decuned Date	CPT Y/N, Date	ART Y/N, N/A	Date	Nutrition Support	Treatment Outcome	Date of Heatillerin Outcome	comments
									1			!					1				<u> </u>				T												T						_							
									$\dashv$								$\dagger$								$\dagger$		+										$\dagger$													
						<u> </u>			$\dashv$								$\dagger$								$\dagger$												$\dagger$		1							$\dagger$	$\dagger$		$\dagger$	
									+								$\top$																				T													
																					•												•					-												

Notation method for recording smears								
Report	Interpretation							
o	No AAFB seen							
Scanty	1-9 AFB per 100HPF							
+	>10-99 AFB per 100HPF							
++	>1-10 AFB in 50HPF							
+++	>10 AFB in 20HPF							

Notation method for recording cultures									
Growth	G								
No Growth	NG								
Non tuberculous mycobacteria isolated but no growth of MTB	NG (NTM)								
Contaminated	С								

	Drug Abbı
Н	Isoniazid
R	Rifampicin
Е	Ethambutol
Z	Pyrizinamide
S	Streptomycin
Bdq	Bedaquiline
Cfz	Clofazimine
Amx/clv	Amoxicillin Clavulin
Dlm	Delamind
Am	Amicacin

Dieviations	
Km	Kanamycin
Lfx	Levofloxacin
Mfx	Moxifloxacin
Pto	Prothionamide
Eto	Ethionamide
Cs	Cycloserine
PAS	P-aminosallic Acid
Imp	Imipinem
HDI	High doze Isoniazid
Lzd	linezolid
	Km Lfx Mfx Pto Eto Cs PAS Imp HDI

Outcome Treatment	
С	Cured
TC	Treatment Complete
D	Dead
LTFU	Lost to follow up
F	Treatment failure
NE	Not Evaluated



National Tuberculosis, Leprosy and Lung Disease Program

1<sup>st</sup> Floor, Afya Annex, Kenyatta National Hospital Grounds
P.O. Box 20781 – 00202 Nairobi

Email: info@nltp.co.ke

www.nltp.co.ke



